Success Metrics

Clinical Success Rate
25.0%

Based on 1 completed trials

Completion Rate
25%(1/4)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
3(75%)

Phase Distribution

Ph phase_3
4
100%

Phase Distribution

0

Early Stage

0

Mid Stage

4

Late Stage

Phase Distribution4 total trials
Phase 3Large-scale testing
4(100.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

25.0%

1 of 4 finished

Non-Completion Rate

75.0%

3 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(1)
Terminated(3)

Detailed Status

Terminated3
Completed1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
25.0%
Most Advanced
Phase 3

Trials by Phase

Phase 34 (100.0%)

Trials by Status

terminated375%
completed125%

Recent Activity

0 active trials
Showing 4 of 4
terminatedphase_3

A Phase III Study Evaluating the Efficacy and Safety of Satavaptan Versus Placebo in Patients With Dilutional Hyponatremia

NCT00728091
completedphase_3

Cirrhotic Ascites Treatment With Satavaptan in Patients With Ascites Due to Cirrhosis of the Liver (CATS)

NCT00358878
terminatedphase_3

Satavaptan in the Prevention of Ascites Recurrence in Patients With Ascites Due to Cirrhosis of the Liver

NCT00359437
terminatedphase_3

Satavaptan for the Prevention of Ascites Recurrence in Patients With Ascites Due to Cirrhosis of the Liver

NCT00366795

Clinical Trials (4)

Showing 4 of 4 trials
NCT00728091Phase 3

A Phase III Study Evaluating the Efficacy and Safety of Satavaptan Versus Placebo in Patients With Dilutional Hyponatremia

Terminated
NCT00358878Phase 3

Cirrhotic Ascites Treatment With Satavaptan in Patients With Ascites Due to Cirrhosis of the Liver (CATS)

Completed
NCT00359437Phase 3

Satavaptan in the Prevention of Ascites Recurrence in Patients With Ascites Due to Cirrhosis of the Liver

Terminated
NCT00366795Phase 3

Satavaptan for the Prevention of Ascites Recurrence in Patients With Ascites Due to Cirrhosis of the Liver

Terminated

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4